Drug intelligence / Profile preview

prostaglandin + timolol (TODDD)

Development stage
Preclinical
Lead developer
Amorphex Therapeutics
Modality
Small Molecules
Administration
Transocular
01

Overview

Amorphex Therapeutics is developing a combination of a prostaglandin analogue and timolol maleate delivered via their proprietary Transocular Drug Delivery Device (TODDD™). The TODDD™ is a soft, flexible, non-invasive ring-like insert placed under the eyelid (transocular/conjunctival fornix) designed for sustained release of medication over several months. This combination therapy targets moderate glaucoma by utilizing two distinct mechanisms: the prostaglandin analogue increases uveoscleral outflow of aqueous humor, while timolol, a non-selective beta-adrenergic antagonist, decreases aqueous humor production. This dual-action approach aims to improve patient compliance and provide consistent intraocular pressure (IOP) control compared to daily eye drops.

Brand names
TODDD
Other names
TODDD + Prostaglandin and Timolol
02

Targets

ADRB1 (β1)ADRB2 (β2)PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on prostaglandin + timolol (TODDD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prostaglandin + timolol (TODDD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call